PubMed Health⌕ Search

Biomedical subjects

L A Sanchez

Publications and source records attributed to L A Sanchez.

At least 73 records · Page 4Linked to original sources
PubMed1994

Is percutaneous balloon angioplasty appropriate in the treatment of graft and anastomotic lesions responsible for failing vein bypasses?

We reviewed 95 cases of vein graft and anastomotic lesions treated with percutaneous transluminal balloon angioplasty (PTA) and 30 cases treated surgically. The therapy was deemed a failure if the lesion recurred or if the graft closed. The 21-month patency rate of lesions treated surgically was 86%, which was significantly better than the 42% patency rate for all lesions treated with PTA (P < 0.01). An evaluation of the lesion and graft characteristics that could influence the patency of stenotic lesions treated with PTA included: lesion length, minimum graft diameter, lesion location, and lesion type. The 66% patency rate at 24 months for the 41 simple lesions (single, nonrecurrent, < 15 mm in length, and within grafts > or = 3 mm minimal diameter) was significantly better than the 17% patency rate for the 50 complex lesions (multiple, recurrent, > or = 15 mm in length, or within grafts < 3 mm in minimal diameter) (P < 0.01). In addition, the 21-month patency rate for the surgically treated group (86%) was not significantly better than that of the angioplasty-treated simple lesions (66%). When feasible, vein graft lesions are best treated with simple surgical interventions. PTA can be useful to maintain the patency of severely compromised grafts prior to surgical repair, to treat simple lesions difficult to reach surgically, and for patients with medical contraindications for an operation.

Aged↗
PubMed1994

Transfemoral endovascular stented graft treatment of aorto-iliac and femoropopliteal occlusive disease for limb salvage.

BACKGROUND: Endovascular stented grafts employ a new technique that blends intravascular stent and prosthetic graft technologies. These devices may be used to treat arterial aneurysms, occlusive disease, and vascular injuries. This report describes the application of stented grafts to the treatment of limb-threatening ischemia secondary to occlusive disease of the aorta, iliac, and femoral arteries. METHODS: Three patients with limb-threatening ischemia and severe comorbid medical illnesses were treated with transvascular stented grafts that were composed of 6-mm thin-walled polytetrafluoroethylene grafts and Palmaz balloon expandable stents. The grafts were inserted through a cutdown in an artery remote from the site of occlusion and introduced into the vascular system within 14-Fr introducer sheaths. RESULTS: Technical success was documented in all three patients with restoration of arterial continuity following stent graft deployment. Patency and limb salvage has been achieved to 1 year. One patient required further dilatation of the proximal stent at 6 weeks. Complications were limited to an iliofemoral deep vein thrombosis in one patient. CONCLUSIONS: Endovascular stented grafts can be inserted to treat limb-threatening ischemia. Although these initial results are encouraging, greater experience in more patients observed for longer periods of time is necessary before this technique can be advocated for widespread use.

Aortic Diseases↗
PubMed1994

Use and misuse of pharmacoeconomic terms: a definitions primer.

Given the current cost-conscious health care environment, pharmacists must now be able to assess the effects of an agent from safety, efficacy, and value considerations. This article describes the various methodologies that may be used in performing pharmacoeconomic analyses and highlights the use and misuse of pharmacoeconomic terminology. Case studies relating the use of these methods to the pharmacy practice setting are presented. The technical nuances of the various methods are explained to promote a better understanding of the appropriate use of these techniques and the terminology used to describe them.

Cost-Benefit Analysis↗
PubMed1993

Analysis of balloon dilatation of human vein graft stenoses.

Controversy continues as to whether percutaneous transluminal angioplasty (PTA) or surgical revision is the ideal modality for the treatment of failing grafts. This prompted a histopathologic analysis of failing human vein graft segments subjected to ex vivo balloon dilatation to define variables responsible for the discrepant results. Fifteen vein graft lesions from 14 patients with failing infrainguinal bypasses were recovered after surgical excision. Each graft lesion was focal and uniform in length (2.1 +/- 0.3 cm). Rings sectioned from adjacent regions of each vein graft lesion before and after balloon inflation were processed for histologic study, photomicrography, and image analysis. Angioplasty balloon size was selected on the basis of preoperative arteriograms. Graft lesions were divided into three groups based on lesion thickness and the degree of fibrosis and cellularity seen on sections stained with Masson's trichrome. The luminal area before angioplasty was not significantly different for the three groups (p > 0.2). Vein grafts with thick intimas (group 1) had significantly less luminal dilatation after angioplasty as compared with less thick intimal lesions (groups 2 and 3; p < 0.001). Those lesions with varying degrees of cellularity (groups 2 and 3) showed no significant differences in luminal diameter after angioplasty. However, the cellular lesions in group 2 consistently formed multiple intimal flaps that could produce PTA failures even with good luminal restoration. The varying histology of vein graft lesions and associated differences in intimal thickness and cellularity may be responsible for the inconsistent results following PTA. Estimates of wall thickness before angioplasty, particularly in the intimal area, may be helpful in evaluating which lesions might benefit most from PTA.

Angioplasty, Balloon↗
PubMed1993

Is surveillance to detect failing polytetrafluoroethylene bypasses worthwhile?: Twelve-year experience with ninety-one grafts.

PURPOSE: The purpose of this study was to review the 91 failing polytetrafluoroethylene (PTFE) grafts that were treated at our institution over the past 12 years to better understand their cause and improve the diagnosis and treatment of these grafts. METHODS: Eighty-five patients with 91 failing grafts were retrospectively reviewed. The 144 graft-threatening lesions associated with these grafts were characterized by location (inflow artery, outflow artery, anastomosis, or graft body) and treatment method used (surgery, balloon angioplasty, or thrombolysis). RESULTS: Progression of atherosclerotic disease was the predominant cause of failing PTFE grafts with 43 inflow lesions and 83 outflow lesions, accounting for 87% of all lesions identified. Ten lesions (7%) were noted within the prosthetic grafts, whereas only eight (6%) lesions were noted at the anastomoses. Forty stenotic lesions 2 cm in length or less were treated with percutaneous transluminal balloon angioplasty, whereas 100 lesions were treated by patch angioplasty or graft extensions. The remaining four lesions, present within the prosthetic grafts, were treated with thrombolytic therapy. The 5-year cumulative patency rate for all failing PTFE grafts was 71%, whereas that of failing femoropopliteal PTFE grafts was 64%. The 5-year limb salvage rate for all failing PTFE grafts was 73%. CONCLUSIONS: The progression of inflow and outflow disease is the predominant cause of failing PTFE grafts, which suggests that this process is a more important cause of PTFE graft thrombosis than is generally recognized. Frequent PTFE graft surveillance may permit detection of some threatening lesions before graft thrombosis occurs and may help maintain and prolong graft patency. The enhanced 5-year patency and limb salvage rates for treated failing PTFE grafts compared with the known poor outcome after reinterventions for PTFE graft failure support the conclusion that surveillance of PTFE grafts is worthwhile.

Adult↗
PubMed1991

A ten-year experience with one hundred fifty failing or threatened vein and polytetrafluoroethylene arterial bypass grafts.

Between Jan. 1, 1980, and Dec. 31, 1989, 2187 infrainguinal revascularization procedures were performed. In 130 of these cases with patent bypasses, hemodynamic deterioration was suspected, and urgent arteriography was performed. Twenty additional patients with aortofemoral, femorofemoral, or axillofemoral bypasses demonstrated hemodynamic deterioration. In 93% of failing grafts the condition was suspected because of recurrent symptoms or changes in the pulse examination. Two hundred eighty-five high-grade stenotic or occlusive lesions were identified in inflow arteries, outflow arteries, within the graft, or at proximal or distal anastomoses associated with these 150 grafts. One hundred sixty-one (57%) of these lesions were in patients with failing vein grafts; 115 (40%) were in patients with failing polytetrafluoroethylene (PTFE) grafts; and 9 (3%) were associated with failing composite vein/PTFE grafts. Stenotic lesions less than 5 cm in length were initially treated with percutaneous transluminal balloon angioplasty (PTA). Occlusive lesions, stenoses greater than 5 cm in length, and PTA failures were treated surgically. The overall 6-year cumulative secondary patency rate for failing grafts was 65%, and the limb salvage rate was 75%. The extended patency rate after the first intervention in the failing state was 56% at 5 years. The 5-year secondary patency rate for grafts initially treated with PTA (58%) was not significantly different (p = 0.25) from that for grafts treated initially with surgery (71%). Percutaneous transluminal angioplasty was effective for inflow stenoses of the iliac, femoral, and popliteal arteries and for some outflow lesions.(ABSTRACT TRUNCATED AT 250 WORDS)

Angioplasty, Balloon↗
PubMed1991

Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature.

The varied interpretations of the term "cost-effective" in the pharmacy literature are discussed and the soundness of pharmacoeconomic analyses is assessed. Sixty-five studies concerning cost issues, which were published by six pharmacy journals from January 1985 to December 1990, were evaluated according to 10 methodological criteria. Two investigators independently reviewed each study and completed a data collection form; differences were discussed and resolved to ensure consistency of evaluation. In 36 (55%) of 65 articles, cost-effectiveness was misinterpreted as cost saving. Only 3 of the 10 criteria were fulfilled by 50% or more of the studies evaluated. Problem areas included the following: (1) identification of relevant costs and consequences of each strategy, (2) discounting--adjusting data to reflect the differential timing of costs and consequences, (3) incremental analysis--examining extra costs of a program relative to additional effects provided, and (4) sensitivity analysis. Many pharmacoeconomic studies inappropriately used the term "cost-effective" and inadequately addressed basic methodological components of an economic evaluation.

Cost Savings↗
PubMed1990

Interruption of critical aortoiliac collateral circulation during nonvascular operations: a cause of acute limb-threatening ischemia.

In patients with aortoiliac occlusive disease interruption of critical collaterals during another nonvascular or cardiac operation may threaten limb viability. This occurred in four patients whose limb-threatening ischemia was precipitated by radical cystectomy with bilateral hypogastric artery ligation, left colon resection, or coronary artery revascularizations by means of the internal mammary artery. Important collateral pathways, the interruption of which may account for this phenomenon, are detailed, and approaches are outlined for prevention and management of acute ischemia in this setting.

Acute Disease↗
PubMedDate not supplied

Endovascular repair of aortoiliac occlusive disease.

Occlusive disease of the aorta and iliac and femoral arteries may lead to limb-threatening ischemia when multiple levels of disease are present. The combined treatment of severe aortoiliac and infrainguinal disease using standard techniques may be hazardous or contraindicated in patients with multiple, previous reconstructions or severe co-morbid medical illnesses. This report summarizes the technical feasibility and early results of aortoiliac endovascular stented grafts (ESGs) in combination with conventional surgical reconstructions for the treatment of multilevel arterial occlusive disease. Forty-two patients with multilevel aortoiliofemoral limb-threatening occlusive disease had an ESG inserted to treat long-segment, multilevel, occlusive disease. ESGs originated from either the aorta or the common iliac artery and were inserted into one of the femoral arteries. ESG lengths ranged from 16 to 30 cm (mean 21 cm). Conventional surgical bypasses were constructed, when necessary, from polytetrafluoroethylene (PTFE) or saphenous vein and were extended using standard techniques to the popliteal, tibial, or contralateral femoral arteries. Technical success of graft insertion was achieved in 39 of 42 attempted ESG procedures (93%). The 18-month primary and secondary cumulative patency rates for ESGs were 89 +/- 9 (SE) and 100%, respectively. Limb salvage was achieved in 94% of patients at 24 months. Four patients had minor postprocedure complications (10%), and there was one death. Endovascular aortoiliac grafts, often in combination with conventional surgical infrainguinal bypasses, are a technically feasible, potentially safe option for the treatment of limb-threatening aortoiliofemoral occlusive disease and have demonstrated encouraging early patency. Long-term follow-up is necessary before widespread application of this technique is instituted.

Aged↗
PubMedDate not supplied

Effect of polytetrafluoroethylene covering of Palmaz stents on the development of intimal hyperplasia in human iliac arteries.

PURPOSE: The occurrence of neointimal hyperplasia within a stent may result in restenosis with recurrent symptoms of end-organ ischemia. This study evaluated the potential of a nonporous covering of a stent to function as a barrier to the formation of intrastent neointimal hyperplasia. MATERIALS AND METHODS: Twelve endovascular stent grafts were used to treat 12 high-risk patients with limb-threatening ischemia secondary to long-segment iliac artery occlusion. A 6-mm, thin-walled polytetrafluoroethylene graft was inserted and anchored to the common iliac artery with use of Palmaz stents. Each stent was covered by graft material over one-half of its length. Control angiograms obtained immediately after graft insertion were compared with follow-up angiograms obtained between 4 and 6 months after the initial procedure. On each angiogram, the region of the stent was magnified by 20x to permit computerized luminal diameter measurements. RESULTS: The mean luminal diameter within the stent was significantly greater on the covered (7.7 mm +/- 0.33 standard deviation) compared with the uncovered (6.7 mm +/- 0.85 standard deviation) portions (P < .01). CONCLUSIONS: Partially covered stents are a unique model for assessing the effects of an extrinsic stent covering on arterial healing and myointimal hyperplasia. These data suggest that a relatively nonporous covering of polytetrafluoroethylene may inhibit stent-related restenosis in iliac arteries.

Aged↗